Literature DB >> 31527173

Trends in Off-Label Drug Use in Ambulatory Settings: 2006-2015.

Divya Hoon1, Matthew T Taylor2,3, Pooja Kapadia1, Tobias Gerhard2,4,5, Brian L Strom2,6,7, Daniel B Horton8,5,9.   

Abstract

BACKGROUND: Off-label drug use in children is common and potentially harmful. In most previous off-label use research, authors studied hospitalized children, specific drug classes, or non-US settings. We characterized frequencies, trends, and reasons for off-label systemic drug orders for children in ambulatory US settings.
METHODS: Using nationally representative surveys of office-based physicians (National Ambulatory Medical Care Surveys, 2006-2015), we studied off-label orders of systemic drugs for children age <18 based on US Food and Drug Administration-approved labeling for age, weight, and indication. We characterized the top classes and diagnoses with off-label orders and analyzed factors and trends of off-label orders using logistic regression.
RESULTS: Physicians ordered ≥1 off-label systemic drug at 18.5% (95% confidence interval: 17.7%-19.3%) of visits, usually (74.6%) because of unapproved conditions. Off-label ordering was most common proportionally in neonates (83%) and in absolute terms among adolescents (322 orders out of 1000 visits). Off-label ordering was associated with female sex, subspecialists, polypharmacy, and chronic conditions. Rates and reasons for off-label orders varied considerably by age. Relative and absolute rates of off-label orders rose over time. Among common classes, off-label orders for antihistamines and several psychotropics increased over time, whereas off-label orders for several classes of antibiotics were stable or declined.
CONCLUSIONS: US office-based physicians have ordered systemic drugs off label for children at increasing rates, most often for unapproved conditions, despite recent efforts to increase evidence and drug approvals for children. These findings can help inform education, research, and policies around effective, safe use of medications in children.
Copyright © 2019 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31527173      PMCID: PMC7286122          DOI: 10.1542/peds.2019-0896

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  37 in total

1.  Unlicensed and off label drug use by children in the community: cross sectional study.

Authors:  Eric Schirm; Hilde Tobi; Lolkje T W de Jong-van den Berg
Journal:  BMJ       Date:  2002-06-01

Review 2.  Off-label use of drugs in children.

Authors:  Daniel A Frattarelli; Jeffrey L Galinkin; Thomas P Green; Timothy D Johnson; Kathleen A Neville; Ian M Paul; John N Van Den Anker
Journal:  Pediatrics       Date:  2014-02-24       Impact factor: 7.124

3.  Prioritizing Pediatric Drug Research Using Population-Level Health Data.

Authors:  James A Feinstein; Elaine H Morrato; Chris Feudtner
Journal:  JAMA Pediatr       Date:  2017-01-01       Impact factor: 16.193

4.  Enhancing the Pediatric Drug Development Framework to Deliver Better Pediatric Therapies Tomorrow.

Authors:  Christina Bucci-Rechtweg
Journal:  Clin Ther       Date:  2017-08-14       Impact factor: 3.393

5.  Off label use of prescription medicines in children in outpatient setting in Estonia is common.

Authors:  Jana Lass; Alar Irs; Heti Pisarev; Triin Leinemann; Irja Lutsar
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-05       Impact factor: 2.890

6.  Outpatient antidepressant drug use in children and adolescents in Germany between 2004 and 2011.

Authors:  Carsten Schröder; Michael Dörks; Bianca Kollhorst; Tilo Blenk; Ralf W Dittmann; Edeltraut Garbe; Oliver Riedel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-11-20       Impact factor: 2.890

7.  Paediatric drug use with focus on off-label prescriptions in Lombardy and implications for therapeutic approaches.

Authors:  Carla Carnovale; Valentino Conti; Valentina Perrone; Stefania Antoniazzi; Marco Pozzi; Luca Merlino; Mauro Venegoni; Emilio Clementi; Sonia Radice
Journal:  Eur J Pediatr       Date:  2013-08-03       Impact factor: 3.183

8.  Pediatric drug labeling: improving the safety and efficacy of pediatric therapies.

Authors:  Rosemary Roberts; William Rodriguez; Dianne Murphy; Terrie Crescenzi
Journal:  JAMA       Date:  2003-08-20       Impact factor: 56.272

9.  Appropriateness of outpatient antibiotic prescribing among privately insured US patients: ICD-10-CM based cross sectional study.

Authors:  Kao-Ping Chua; Michael A Fischer; Jeffrey A Linder
Journal:  BMJ       Date:  2019-01-16

10.  National trends in off-label use of atypical antipsychotics in children and adolescents in the United States.

Authors:  Minji Sohn; Daniela C Moga; Karen Blumenschein; Jeffery Talbert
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

View more
  16 in total

1.  Off-Label Drug Use in Pediatric Out-Patient Care: A Multi-Center Observational Study.

Authors:  Aeshah AlAzmi; Zahra Alasmari; Consuela Yousef; Ahmed Alenazi; Mohammed AlOtaibi; Hani AlSaedi; Adnan AlShaikh; Amani AlObathani; Omaima Ahmed; Loie Goronfolah; Mousa Alahmari
Journal:  Hosp Pharm       Date:  2020-08-31

Review 2.  Prescribing drugs to overweight and obese children: Balancing efficacy and safety.

Authors:  Helene Roy; Christel Bertoldi; Catherine Farrell; Elisabeth Rousseau
Journal:  Paediatr Child Health       Date:  2021-01-21       Impact factor: 2.253

3.  Leveraging Case Narratives to Enhance Patient Age Ascertainment from Adverse Event Reports.

Authors:  Phuong Pham; Carmen Cheng; Eileen Wu; Ivone Kim; Rongmei Zhang; Yong Ma; Cindy M Kortepeter; Monica A Muñoz
Journal:  Pharmaceut Med       Date:  2021-09-02

4.  Type 2 diabetes in youth: Rationale for use of off-label antidiabetic agents.

Authors:  Megan M Kelsey; Philip S Zeitler; Kristen J Nadeau; Amy S Shah
Journal:  Pediatr Diabetes       Date:  2022-05-16       Impact factor: 3.409

5.  Valproic Acid Induced Pancreatitis Presenting With Decreased Level of Consciousness in a Child With Tuberous Sclerosis Complex.

Authors:  Pierre-Charles Deschenes; Julie Autmizguine; Philippe Major; Niina Kleiber
Journal:  J Pediatr Pharmacol Ther       Date:  2020

Review 6.  A Scoping Review of Medications Studied in Pediatric Polypharmacy Research.

Authors:  Alexis E Horace; Negar Golchin; Elia M Pestana Knight; Neal V Dawson; Xuan Ma; James A Feinstein; Hannah K Johnson; Lawrence Kleinman; Paul M Bakaki
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

7.  Aversion to Off-label Prescribing in Clinical Pediatric Weight Management: The Quintessential Double Standard.

Authors:  Christine B San Giovanni; Brooke Sweeney; Joseph A Skelton; Megan M Kelsey; Aaron S Kelly
Journal:  J Clin Endocrinol Metab       Date:  2021-06-16       Impact factor: 5.958

8.  The best pharmaceuticals for children-what can we do?

Authors:  Hao Li; Fang-Hong Shi; Shi-Ying Huang; Shun-Guo Zhang; Hui-Wen Chen
Journal:  Transl Pediatr       Date:  2020-04

9.  Impacts of Psychopharmaceuticals on the Neurodevelopment of Aquatic Wildlife: A Call for Increased Knowledge Exchange across Disciplines to Highlight Implications for Human Health.

Authors:  Stephanie J Chan; Veronica I Nutting; Talia A Natterson; Barbara N Horowitz
Journal:  Int J Environ Res Public Health       Date:  2021-05-12       Impact factor: 3.390

10.  Association of Selective Serotonin Reuptake Inhibitors With the Risk of Type 2 Diabetes in Children and Adolescents.

Authors:  Jenny W Sun; Sonia Hernández-Díaz; Sebastien Haneuse; Florence T Bourgeois; Seanna M Vine; Mark Olfson; Brian T Bateman; Krista F Huybrechts
Journal:  JAMA Psychiatry       Date:  2021-01-01       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.